Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch ReliefZacks Investment Research • Thursday
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic DermatitisBusiness Wire • Wednesday
ZTS Q3 Earnings Top Estimates, 2026 Profit Outlook Improves, Stock UpZacks Investment Research • 11/05/26
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS GuidanceBusiness Wire • 11/05/26
Zoetis: Near-Term Expectations More Achievable, Long Growth Runway UndervaluedSeeking Alpha • 11/04/26
Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key MetricsZacks Investment Research • 11/03/26
Zoetis (ZTS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseZacks Investment Research • 10/29/26
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 10/23/26
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?Zacks Investment Research • 10/21/26
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection TreatmentBusiness Wire • 10/20/26